Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...

A groundbreaking study shows how Zepbound, a popular weight loss medication, could become a key treatment for heart failure ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

(Reuters) -Eli Lilly on Thursday suggested ... about signs of weakness in sales of the drugs. Lilly said on a call with analysts that it still believed there was huge demand for its weight-loss drug ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

INDIANAPOLIS — Eli Lilly’s profit ... Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment ...